A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Isatuximab (Primary) ; Lenalidomide (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Melphalan; Stem cell therapies
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Oct 2018 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 18 Oct 2018.
- 14 Aug 2018 New trial record